Serial 3T MRI in early Parkinson’s to validate PD progression markers: Rationale and MRI analysis plan for nigral depigmentation at baseline, 6- and 12-months’ follow-up

Access to these files may be requested. Please contact Dr Xing at [e-mail]. While NM-MRI has shown promise in diagnosing PD, its potential as a progression marker, particularly in the early stages when disease-modifying treatments are most effective, remains relatively unexplored. Our InsIghtPD study focuses on evaluating the substantia nigra, primarily looking at nigral depigmentation at baseline, 6- and 12-months’ follow-up. Secondary metrics, such as free water, kurtosis, and susceptibility, are also examined. Additionally, the study explores other whole brain metrics with potential as progression markers. The goal is to understand the minimal detectable change in these MRI metrics during the early clinical phase of PD. Furthermore, the study seeks to differentiate PD-related pathological changes from the effects of natural aging, which is critical for accurately assessing disease progression.